01—Abstract
Summary
Summary of the 8-K filed January 10, 2025. Cited figures are marked; the original filing is the authoritative source.
On January 10, 2025, Royalty Pharma plc disclosed that its subsidiary, Royalty Pharma Holdings Ltd. (RPH), entered into a Membership Interests Purchase Agreement to acquire all equity interests in Royalty Pharma, LLC and RP Management, LLC, the external manager that conducts all of the company's business and operations.
Consideration consists of $200 milliona in cash, less 2025 management fee payments received by the manager from January 1, 2025 through closing, plus 24,530,266 non-voting RPH shares. RPH will also assume RP Management's $380 million term loan facility. The Share Consideration to Pablo Legorreta vests straight-line over five years, and the other management members' shares vest over nine years.
The company's press release estimates total transaction value of approximately $1.1 billionb based on a $26.20 share price on January 8, 2025, and expects cumulative cash savings of more than $1.6 billion over ten years, with annual savings above $100 million in 2026 and above $175 million in 2030. The transaction is expected to close in the second quarter of 2025, requires shareholder approval, and can be terminated if not consummated by August 1, 2025. Voting agreements covering approximately 25% of fully diluted shares have been signed by board and senior management members.
The same day, the board approved a new $3 billionc share repurchase program that replaces the unused $465 million of the March 2023 $1 billion program. Management intends to repurchase $2 billion of shares in 2025, subject to market conditions, with the total depending on the discount to intrinsic value. The company stated that capital deployment guidance of $2.0 to $2.5 billion per year, its dividend growth commitment of mid-single digit percentages annually, and its investment grade credit rating commitment are unchanged.
The filing also furnishes a press release, an investor presentation, and a transcript of the investor call. Management stated that the Share Consideration represents approximately 4%d of shares outstanding, assuming all shares vest, and that the management fee currently paid to the manager is 6.5% of Portfolio Receipts plus 0.25% of the value of security investments.
02—Key points
Key Highlights
- Royalty Pharma will acquire its external manager, RP Management, LLC, for about $100 million in net cash (after 2025 management fee offsets), assumption of $380 million in manager debt, and 24,530,266 non-voting RPH shares, which the company values at roughly $1.1 billion in total.
- Expected annual cash savings are greater than $100 million in 2026 and greater than $175 million in 2030, with cumulative savings of more than $1.6 billion over ten years, according to the press release.
- Most of the share consideration vests over five to nine years, with Pablo Legorreta's shares vesting over five years and other management members' shares vesting over nine years, which the company says aligns management with shareholders.
- The board approved a new $3 billion share repurchase program, replacing the $465 million remaining under the March 2023 $1 billion program, with $2 billion intended for repurchases in 2025 subject to market conditions.
- The transaction requires shareholder approval and is expected to close in the second quarter of 2025; it may be terminated if not completed by August 1, 2025.
- Board members and senior management who control approximately 25% of fully diluted shares have signed voting agreements in favor of the transaction.
- The company states that its capital deployment guidance of $2.0 to $2.5 billion per year, its mid-single digit percentage dividend growth commitment, and its investment grade credit rating commitment are unchanged.
03—Questions
Frequently Asked Questions
What is Royalty Pharma acquiring, and what does it pay?
Royalty Pharma Holdings Ltd. is acquiring all equity interests in RP Management, LLC and Royalty Pharma, LLC from the sellers. The consideration is $200 million in cash, less the 2025 management fee payments the manager receives from January 1, 2025 through closing, plus 24,530,266 non-voting RPH shares. The company also assumes RP Management's $380 million term loan facility.
How does the transaction affect the company's costs and cash flow?
The press release says the internalization is expected to produce cash savings of greater than $100 million in 2026, growing to greater than $175 million in 2030, and cumulative savings of more than $1.6 billion over ten years. The company states that eliminating the management fee will also increase net returns on investments and that the transaction is expected to be immediately accretive to Portfolio Cash Flow.
How much stock will be issued, and when does it vest?
The company will issue 24,530,266 non-voting RPH shares, which the press release says equals approximately 4% of shares outstanding assuming all shares vest. Pablo Legorreta's shares vest straight-line over five years, and the other management members' shares vest straight-line over nine years, beginning January 1, 2025.
What is the new share repurchase program and how much will be bought in 2025?
The board authorized a $3 billion share repurchase program that replaces the unused $465 million of the company's original $1 billion program from March 2023. The company intends to repurchase $2 billion of shares in 2025, subject to market conditions, and the total repurchased depends on the discount to intrinsic value at which the shares trade.
What are the conditions and timing for closing the transaction?
Closing is subject to customary conditions, including shareholder approval, expiration of the HSR waiting period, and requisite investor consents. The company expects the transaction to close in the second quarter of 2025. Either party may terminate if the transaction is not consummated by August 1, 2025, under customary termination rights.
04—Continue